Signaturefd LLC Buys 946 Shares of Hims & Hers Health, Inc. $HIMS

Signaturefd LLC lifted its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 36.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,532 shares of the company’s stock after purchasing an additional 946 shares during the quarter. Signaturefd LLC’s holdings in Hims & Hers Health were worth $176,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in HIMS. Public Employees Retirement System of Ohio bought a new stake in shares of Hims & Hers Health in the 4th quarter worth approximately $99,000. Wealth Enhancement Advisory Services LLC purchased a new position in Hims & Hers Health in the 4th quarter worth approximately $213,000. Rhumbline Advisers raised its holdings in Hims & Hers Health by 15.7% in the 1st quarter. Rhumbline Advisers now owns 597,331 shares of the company’s stock worth $17,651,000 after acquiring an additional 81,107 shares during the last quarter. RFG Advisory LLC purchased a new position in Hims & Hers Health in the 1st quarter worth approximately $427,000. Finally, Diligent Investors LLC purchased a new position in Hims & Hers Health in the 1st quarter worth approximately $322,000. 63.52% of the stock is owned by institutional investors.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 85,000 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $60.20, for a total transaction of $5,117,000.00. Following the sale, the chief financial officer directly owned 70,232 shares in the company, valued at $4,227,966.40. This represents a 54.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Soleil Boughton sold 2,637 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $58.79, for a total value of $155,029.23. Following the sale, the insider owned 163,767 shares in the company, valued at approximately $9,627,861.93. This trade represents a 1.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,622,727 shares of company stock valued at $83,566,691. Corporate insiders own 13.71% of the company’s stock.

Hims & Hers Health Trading Down 9.1%

Shares of Hims & Hers Health stock opened at $52.61 on Friday. The company has a market capitalization of $11.89 billion, a P/E ratio of 65.77, a P/E/G ratio of 3.91 and a beta of 2.25. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The company has a fifty day moving average of $51.47 and a 200 day moving average of $47.16. Hims & Hers Health, Inc. has a fifty-two week low of $16.69 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm’s revenue was up 72.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of recent analyst reports. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Canaccord Genuity Group restated a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a report on Saturday, September 27th. UBS Group set a $30.00 target price on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, Truist Financial decreased their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research note on Monday, August 18th. Two equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Hims & Hers Health has an average rating of “Reduce” and a consensus target price of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.